Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.5 USD | +4.19% | +0.95% | -30.67% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.67% | 5.04B | |
+1.20% | 91.72B | |
0.00% | 39.44B | |
-8.52% | 34.47B | |
+64.13% | 26.7B | |
-17.37% | 15.13B | |
-5.99% | 13.27B | |
-10.69% | 11.74B | |
-47.78% | 10.54B | |
+8.09% | 9.41B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing